PubMed ID:
14681504
Public Release Type:
Journal
Publication Year: 2003
Affiliation: University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.
DOI:
https://doi.org/10.1056/NEJMoa030656
Authors:
Kusek JW,
Andriole GL Jr,
Bautista OM,
Roehrborn CG,
McConnell JD,
Medical Therapy of Prostatic Symptoms (MTOPS) Research Group,
Smith JA,
Slawin KM,
Schenkman NS,
Ramsdell JW,
Milam DF,
Menon M,
Miller GJ,
Lucia MS,
Lieber MM,
Kreder KJ,
Kaplan SA,
Jacobs SC,
Foster HE,
Foley JP,
Diokno A,
Crawford ED,
Clarke HS,
Nyberg LM Jr,
McVary KT,
Lepor H,
Dixon CM
Studies:
Medical Therapy of Prostatic Symptoms
Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.